Statement of problem: Evaluating the effectiveness of treatments in chronic rhinosinusitis (CRS) have been limited by both a paucity of high quality randomised trials, and the heterogeneity of outcomes in those that have been reported.
Introduction
CRS represents a common and widespread source of ill health, with 11% of UK adults reporting CRS symptoms in a worldwide population study (1) . CRS has been shown to have a major impact on quality of life that is reportedly greater in several domains of the SF-36 than angina or chronic respiratory disease (2) . Acute exacerbations, inadequate symptom control and respiratory disease exacerbation are common amongst this population.
Longitudinal primary care data from the Clinical Practice Re-search Datalink (CPRD) data shows that 1% of UK adults receive treatment from their GP each year with an average of 4 GP visits per year, receiving multiple prescribed medical treatments and with 91% of rhinosinusitis patients receiving an antibiotic prescription (3) . There is a significant cost of the disease to the patient and healthcare systems, but also significant indirect costs through absenteeism and presenteeism. The total direct cost attributed to management of CRS is estimated to reach $11 billion per year in the USA (4) . An earlier systematic review showed that the direct healthcare costs in the USA attributed to CRS is approximately $6.9 -9.9 billion per annum, with indirect cost to society through lost productivity estimated at $13 billion per annum (5) .
There is considerable variation in current practice, both in terms of antibiotic prescribing and surgical intervention rates (6, 7) . This relates, in part, to the lack of strong recommendations in treatment guidelines. Recently, a suite of Cochrane reviews evaluating the effectiveness of treatments in CRS have been published, but they are limited both by a paucity of high quality randomised trials, and the heterogeneity of outcomes in those that have been reported, which precludes meta-analysis.
Core outcome sets (COS) are an agreed, standardized set of outcomes that should be measured and reported by future trials as a minimum, and are not meant to be restrictive if trialists wish to include additional outcomes. However, inclusion of the core outcomes will facilitate future meta-analysis of trial results in systematic reviews (SRs). The heterogeneity of outcomes currently reported restricts our ability to combine results, and use of a COS may maximize the potential for a trial to contribute to future SRs. Furthermore, the use of core outcome sets also aims to reduce outcome reporting bias, where outcomes are measured but left unreported, often in the setting of negative findings.
The use of a COS is supported by the World Health Organisation (8) and the Cochrane Group for use in reviews of the effects of healthcare interventions, and they have already been developed and adopted by multiple medical and surgical specialties (9) . The development of core outcome sets has been promoted and supported by the COMET (Core Outcome Measures in Effectiveness Trials) Initiative. The success of a COS is likely to be related to its simplicity, and an ideal of 3 -4 main outcome measures were anticipated to be included in the final COS for CRS. Of course, due to the heterogeneity of symptoms that patients with CRS experience and the impact on their quality of life, restricting it to only a few outcomes was likely to be challenging. It should consider both benefits and harms, and initially the core outcome set
should consider 'what' to measure, rather than 'how' to measure it. Although considering trials of effectiveness, the outcomes selected are likely to be relevant to routine clinical practice. In rheumatology, the OMERACT group has developed 9 sets over the last 9 years, and now 70% of clinical trials report the COS.
Although there is no specific methodology, the majority of core outcome sets follow a process of identifying existing knowledge to develop a long list of outcomes, followed by consensus methods using a Delphi process to achieve global agreement between different stakeholder groups, as recommended by COMET (10) .
Materials and methods

COS development registration
The project was registered with the Core Outcome Measures in Effectiveness Trials (COMET) Register, and the development process followed guidance issued by COMET. In particular the 11 minimum standards for COS development (11) were met and the checklist for reporting COS study reporting was followed (12) .
Ethical approval was granted for patient participation in the focus group and Delphi process. Funding was awarded by the British Rhinologic Society to support the COS development.
Defining scope
A steering group of ENT surgeons active in clinical research in the field of CRS was assembled to consider the scope and design of the COS. It was agreed to consider all interventions for CRS, in adult patients (over 18 years). The COS is primarily aimed at research but it was felt that it would also be suitable for routine clinical care. 
Long-list development
A long-list of potential core outcomes was drawn up from a number of sources;
Stakeholder involvement
Both patients, researchers in CRS and physicians (including ENT specialists, Allergists, Respiratory physicians and primary care physicians) were involved in every stage of COS development, including defining scope, developing the long-list, the eDelphi process and review and analysis of the final results.
A Steering Group was convened, consisting of authors of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS)
Guideline, all of whom are actively engaged in research in the The full text articles for the Cochrane systematic reviews were obtained and analysed for eligibility by two independent revie- social media campaign. Using direct emailing, social media and printed cards, an online survey was distributed to a wide range of people involved in the care of patients with CRS. Patients and practitioners were asked to list the 3 outcomes from treatments most important to them. Responses were analysed through development of a thematic framework based on the data.
3) Systematic review of currently available Patient Rated Outcome Measures (PROMs)
A systematic review previously undertaken in 2015 assessed all published PROMS for CRS (15) . All included instruments were screened by 2 independent reviewers (ASJ and RL) to search for items or domains not included in the long list by the first two steps.
4) Patient and Steering Group review
Potential missing items were considered by a patient focus group, and the COS Steering Group, with particular reference to outcomes included in the EPOS guidelines (16) . The long-list was then compiled and mapped to simplified domains for use in the wers (ASJ and RL). As each systematic review presents the results of a number of pooled clinical trials, the published papers for each individual trial were obtained. The bibliographies of the trial papers were further evaluated to identify additional studies for inclusion, not identified within the Cochrane systematic reviews themselves.
Two independent reviewers extracted data from all identified randomised trials. If there was uncertainty or disagreement amongst them, a third reviewer was consulted and had the final say. Each individual outcome was mapped to a core subcategory. These sub-categories were then grouped into core categories. This process has been previously published, with the full methodology and results (13) .
2) Outcomes important to Patients, Practitioners and Providers (OMIPPP)
This pilot project was commissioned by Cochrane UK to identify important outcomes interventions for CRS in adults (14) . It sought the views of a wide range of practitioners (n=155) identified by professional societies and patients (n=80), identified using a on the long-list, but the session was led and supported by an independent, trained facilitator. The facilitator summarised the views of the group and confirmed accuracy prior to concluding the meeting. As the lay definitions were thought to be clear and unambiguous by the Steering group, it was decided that there was no need for additional 'medical definitions' .
Delphi process.
Outcome definitions
A patient focus group was convened to determine the patient's perspective on core outcomes, and create definitions for each outcome. Three ENT members of the Steering Group were available to give a clinical overview for each individual outcome Table 5 . Round 2 median scores by stakeholder group. (10) , participants were able to rate the importance of each item and hence inclusion within the core outcome set. Participants were further asked to submit any outcomes thought to be important but missing from the long-list.
Additional outcomes listed by participants were reviewed and coded by two members of the study team (RH and CH) and new outcomes were included in round 2. In the second round, participants were presented with the aggregate results of ratings for each item (the median score for each item was displayed, separately for each stakeholder group and for the combined cohort), allowing an opportunity of reflection, and were asked to consider each outcome again, using the same scoring system ranking each on a nine-point Likert scale.
Consensus regarding whether an outcome should be included in the COS was defined a priori as 70% or more of the respondents scoring it 7 to 9 and fewer than 15% scoring it as 1 to 3.
Consensus that an outcome should not be included in the COS was defined as 70% or more scoring it as 1 to 3 and fewer than 15% scoring it as 7 to 9. All other score distributions would be taken to indicate lack of agreement for inclusion of a given outcome in the COS. In the event that different stakeholder groups
Item Prioritization
We utilised an online Delphi technique (eDelphi software provided by the COMET initiative) inviting patients and healthcare practitioners to individually rate those outcomes from the longlist that are thought to be essential for core outcome sets. There is currently no standard method for sample size calculation in the Delphi process, and thus a pragmatic approach was taken.
We had aimed to achieve completed responses in round 2 from at least 100 participants, and therefore, allowing for 10% attrition between rounds, aimed to recruit at least 110 participants in the first round.
Participants for the Delphi process were recruited from the Steering Group, with further invitations sent to members of the BRS, ERS and ARS, primary care, allergists and respiratory medicine through the BSACI. Patient participants were recruited from clinical practice. Ethical approval for patient participation in the Delphi process and focus groups was granted.
In the first round, each participant was asked to consider each outcome item, and to decide which were essential to the core outcome set. By using the 10 point scale proposed by the GRADE group (17) , where 1 to 3 signifies an outcome of limited importance, 4 to 6 important but not critical, and 7 to 9 critical IgE levels in serum 3 27 32 52% Table 9 . Remaining items -Items did not reach consensus definition for inclusion in the core outcome set, and were rated by majority of respondents as moderately important. disagreed about the inclusion of specific outcomes in the COS, only items about which there was consensus were included.
Two rounds of the Delphi process were initially planned, with stability measured by consistency of responses between successive rounds of a study and used to determine the value of further rounds (18) . The Steering group and two patient representatives considered the outcomes of each round of the Delphi, and approved the decision to end the Delphi process and the final core outcome set.
Results
Longlist development
The SR identified a total of 83 randomised control trial papers and 8 Cochrane reviews. Of these, 14 trials were excluded, as they were trials that included either paediatric patients, those with allergic rhinitis or published conference abstracts. A total of 69 RCTs were finally obtained and included within this study. No further references were identified through examination of the bibliography of the published systematic reviews or trials. Three hundred and sixty five individual outcomes were extracted from the clinical trials. The trials overlapped in their use of outcomes and between them had used 68 different outcomes and outcome measures. These were then mapped onto twenty-three pre-determined sub-categories, belonging to nine main core categories ( Table 1) .
The OMIPP project generated 653 suggestions of important outcomes from 235 participants. Of these 549 (169 from people with rhinosinusitis, and 380 from practitioners) fitted our description of an outcome. These were mapped onto eight domains and combined with the longlist above ( Figure 1 ; responses grouped under main domains). Of note there was consistency with the domains identified in the SR and those identified with qualitative analysis of the response to the OMIPP project Finally, a focus group of 10 patients with CRS and the Steering group reviewed the list to ensure that no missing items could be identified. A final long-list of 54 items, mapped onto 9 domains was developed (Table 2) .
Delphi Process
The first round of the Delphi process was held in April 2017. One hundred and fourteen participants were recruited, achieving our initial target; this included 8 Steering Group members, 19
patients, and 88 physicians from primary care/allergy/ENT, with ENT surgeons and allergy accounting for 91% of the latter group.
There was close agreement between the Steering group and other healthcare providers (HCPs) ( Table 3 ). In contrast, there were marked differences in responses amongst patients; while patients also rated those items thought by both the Steering Group and other HCPs to be essential to a COS, they also rated almost all clinical measures as essential, even though these were not rated highly by clinicians. Fifteen items were considered essential to the core outcome set by all respondents.
Unfortunately, there was a significant drop-out in respondents between round 1 and 2, despite sending multiple reminders. At round 2, we received 67 replies, representing 59% of our initial cohort. There was a high level of stability in the overall median scores for each item from round 1 to round 2 ( Table 4) . The overall category (not important / moderate importance / essential to COS) only changed in 4 out of 54 items. Twenty-three items had a median score rating the item as essential to the core outcome set. There was much greater consistency in categorical rating between stakeholder groups and it was agreed that there was no need for a third round (Table 5) .
When looking at items that met our definition of consensus, 15
items were considered essential to the core outcome set (Table   6 ), with >70% rating as 7 or more, and less than 15% rating as 3 or less; 1 item was agreed to be unimportant (Table 7) . Overall, 8
items were rated as essential by the majority of respondents but did not reach the 70% threshold (Table 8) , while the remainder were considered to be of moderate importance only, by the majority (Table 9 ).
Thus the final core-outcome set contains 15 items, over 4 domains (Table 10) .
Discussion
While at first glance this list may seem to be too extensive, the items are spread over 4 key domains. Three key patient rated symptoms: nasal obstruction, nasal discharge and sense of smell are included, alongside overall symptom severity and both frequency and duration of symptoms. Repeated use over time of a PROM that includes these symptoms will allow both the symptom scores and duration of symptoms as well as duration of treatment effect to be measured. PROMs such as the SNOT-22 also include items on ability to perform normal daily activity and will evaluate overall disease specific quality of life.
A measure of treatment compliance, alongside evaluation of the side effects of any treatment should be included in future trials, and likely obviates the need for a separate question on acceptability of treatment. Endoscopy scores were considered essential within the outcome set. This is most commonly graded using the Lund-Kennedy score.
Finally a measure of disease control was thought to be important. Control of disease is a concept that combines current disease status or symptom burden and the level of intervention required to get there. The Sinus Control Test is made up of 4 questions, including severity of nasal discharge, nasal obstruction, frequency of symptoms that interfere with normal activity and need for systemic medication in the last 2 weeks (19) . The EPOS guidelines (16) (20) . Key to disease control in all of these control measures is the need for systemic medications -either oral steroids or antibiotics, which could be evaluated alongside the SNOT-22. The need for surgical intervention was rated as an essential outcome in the COS and is also a reflection for disease control. Indeed, a number of trials for biological agents are including avoidance of surgery as an outcome, and particularly in terms of cost-effectiveness evaluation this will be a great One strength of this project is the extensive work to develop the long-list of outcomes, including thematic analysis of views of patients and practitioners and a systematic review of outcomes used in CRS research. Our major limitation is that the response rate between Delphi rounds was lower than expected. This was in part due to delays in between rounds and problems using the electronic Delphi tool, which was newly launched at the time of use. We had planned to undertake 3 rounds, but analysis suggested that stability had been reached and that further rounds, with risk of greater drop out would be unlikely to significantly change the final COS.
It is not intended that these core outcomes are the only outcomes that will be measured by trials of interventions for CRS, and researchers can of course add additional outcomes to suit the needs of specific trials. However, we hope that inclusion of these core outcomes in all future trials will increase the value of future research on interventions for CRS in adults.
Implementation
We plan to seek endorsement from the European and American
Rhinologic Societies in the first instance and ask for the COS to be included in future iterations of International guidelines such as EPOS and ICARS (21) . We will make contact with major funding bodies (eg. NIHR in the UK and NIH in North America) to encourage inclusion of core outcomes in trials at the point of funding.
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